Lonza is responding to the challenges of COVID-19 with employee safety and business continuity as our primary concerns. As a global business, we continue to work together to play a part in this fight against the spread of the coronavirus. This page provides a central hub for news, guidance and other resources.

Latest news

Altimmune Expands AdCOVID Manufacturing Collaboration with Lonza
Lonza to commission a dedicated suite for clinical and commercial supply of Altimmune’s COVID-19 vaccine candidate at its Houston (US) facility
Junshi Biosciences and Lonza Partner to Produce a Neutralizing Antibody Tackling COVID-19
Junshi Biosciences developing therapies for COVID-19 in collaboration with a number of global partners
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
Collaboration goal to enable manufacturing of up to 1 billion doses per year
Join us to control COVID-19
Every day, our employees are working to create a healthier world.

Scientists around the world are working tirelessly to develop and deliver a safe and efficacious vaccine for COVID-19. Currently, there are approximately 50 vaccine candidates in clinical evaluation. Each vaccine type has its own manufacturing needs and challenges, summarized in this fact sheet.

COVID-19 vaccine candidates based on an inactivated virus use a chemically or genetically modified virus. These vaccines are based on an established platform with a low cost of manufacturing, but the scale-up process may be slower than other types.

Vaccines based on a non-replicating viral vector work by delivering vaccine antigens to the selected target cells or tissues. The delivery vehicle is a crippled carrier virus, allowing for a wide range of possible carriers. The productivity of this approach is limited, especially compared to next-gen vaccine platforms.

mRNA-based vaccines represent a novel concept with regulatory guidance being currently developed. Messenger RNA is delivered into target cells, where it is translated into the viral spike protein.

The manufacturing process requires a smaller footprint in comparison to other types. Since the doses are in the microgram range, it is easier to manufacture a high number of doses in a short time frame.

Protein-based vaccines use the whole or a fragment of the viral spike protein. This vaccine platform uses an established manufacturing and purification process for proteins, which can be easily scaled-up.

We know there is a lot of information and guidance at the moment related to the Coronavirus and it is important that we all understand the fundamental information. That’s why we have developed this video to provide a common-sense guide for our employees to managing the Coronavirus. As a global company, we understand that the local situation is different at each of our sites, labs and offices. Regardless of location, the best level of protection is achieved by shared responsibility between our business and our people. We are all accountable for protecting ourselves and our colleagues from the spread of infection. Together we can do this.

The current COVID-19 outbreak is caused by a virus called SARS-CoV-2, belonging to a group of enveloped viruses. The outside layer of these viruses is made of a lipid membrane, which represents a sensitive target.

The best options to destroy viruses on your hands is hand-washing with soap and water or using alcohol-based gels and solutions. For surfaces, you can use bleach, hydrogen peroxide, or solutions containing quaternary ammonium salts. All of these options inactivate the virus by disrupting the lipid membrane or denaturing the viral proteins. This infographic explains basic details about chemical inactivation of SARS-CoV-2.